PHASE II TRIAL OF A SURVIVIN VACCINE (SurVaxM) FOR NEWLY DIAGNOSED GLIOBLASTOMA

被引：0
|
作者：
Ahluwalia, Manmeet [1 ]
Reardon, David [2 ]
Abad, Ajay [3 ]
Curry, William [4 ]
Wong, Eric [5 ]
Peereboom, David [1 ]
Belal, Ahmed [3 ]
Qiu, Jingxin [3 ]
Mogensen, Kathleen [3 ]
Schilero, Cathy [1 ]
Casucci, Danielle [3 ]
Mechtler, Laszlo [3 ]
Uhlmann, Erik [3 ]
Ciesielski, Michael [3 ]
Fenstermaker, Robert [3 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[4] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA
[5] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ATIM-41
引用
收藏
页码：10 / 11
页数：2
相关论文
共 50 条
  • [21] Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study
    Carpentier, Antoine F.
    Verlut, Clotilde
    Ghiringhelli, Francois
    Bronnimann, Charlotte
    Ursu, Renata
    Fumet, Jean David
    Gherga, Elisabeta
    Lefort, Felix
    Belin, Catherine
    Vernerey, Dewi
    Hervieu, Alice
    Laheurte, Caroline
    Meurisse, Aurelia
    Jacquin, Marion
    Malfroy, Marine
    Fagnoni-Legat, Christine
    Lehmann-Che, Jacqueline
    Boullerot, Laura
    Cuzzubbo, Stefania
    Adotevi, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
    Phuphanich, Surasak
    Wheeler, Christopher J.
    Rudnick, Jeremy D.
    Mazer, Mia
    Wang, HongQian
    Nuno, Miriam A.
    Richardson, Jaime E.
    Fan, Xuemo
    Ji, Jianfei
    Chu, Ray M.
    Bender, James G.
    Hawkins, Elma S.
    Patil, Chirag G.
    Black, Keith L.
    Yu, John S.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (01) : 125 - 135
  • [23] Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
    Surasak Phuphanich
    Christopher J. Wheeler
    Jeremy D. Rudnick
    Mia Mazer
    HongQian Wang
    Miriam A. Nuño
    Jaime E. Richardson
    Xuemo Fan
    Jianfei Ji
    Ray M. Chu
    James G. Bender
    Elma S. Hawkins
    Chirag G. Patil
    Keith L. Black
    John S. Yu
    Cancer Immunology, Immunotherapy, 2013, 62 : 125 - 135
  • [24] Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial
    Roth, Patrick
    Gorlia, Thierry
    Reijneveld, Jaap C.
    de Vos, Filip
    Idbaih, Ahmed
    Frenel, Jean-Sebastien
    Le Rhun, Emilie
    Sepulveda, Juan Manuel
    Perry, James
    Masucci, G. Laura
    Freres, Pierre
    Hirte, Hal
    Seidel, Clemens
    Walenkamp, Annemiek
    Lukacova, Slavka
    Meijnders, Paul
    Blais, Andre
    Ducray, Francois
    Verschaeve, Vincent
    Nicholas, Garth
    Balana, Carmen
    Bota, Daniela A.
    Preusser, Matthias
    Nuyens, Sarah
    Dhermain, Frederic
    van den Bent, Martin
    O'Callaghan, Chris J.
    Vanlancker, Maureen
    Mason, Warren
    Weller, Michael
    NEURO-ONCOLOGY, 2024, 26 (09) : 1670 - 1682
  • [25] Phase II trial of bevacizumab and temozolomide for upfront treatment of elderly patients with newly diagnosed glioblastoma.
    Nghiemphu, Phioanh Leia
    Bahng, Hye Hyun
    Lai, Albert
    Faiq, Nadia
    Yong, William H.
    Green, Richard M.
    Polikoff, Jonathan
    Spier, Cynthia Elizabeth
    Iwamoto, Fabio Massaiti
    Lassman, Andrew B.
    Cloughesy, Timothy Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial
    Perez-Larraya, Jaime Gallego
    Ducray, Francois
    Chinot, Olivier
    Catry-Thomas, Isabelle
    Taillandier, Luc
    Guillamo, Jean-Sebastien
    Campello, Chantal
    Monjour, Annick
    Cartalat-Carel, Stephanie
    Barrie, Maryline
    Huchet, Aymeri
    Beauchesne, Patrick
    Matta, Mona
    Mokhtari, Karima
    Tanguy, Marie-Laure
    Honnorat, Jerome
    Delattre, Jean-Yves
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) : 3050 - 3055
  • [27] Challenges in the development of a survivin vaccine ( SurVaxM) for malignant glioma
    Fenstermaker, Robert A.
    Ciesielski, Michael J.
    EXPERT REVIEW OF VACCINES, 2014, 13 (03) : 377 - 385
  • [28] Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma -: A phase II study
    Weller, M
    Streffer, J
    Wick, W
    Kortmann, RD
    Heiss, E
    Küker, W
    Meyermann, R
    Dichgans, J
    Bamberg, M
    CANCER, 2001, 91 (02) : 423 - 427
  • [29] Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma
    Wen, PY
    Gigas, DC
    MacDonald, L
    Batchelor, TT
    Schiff, D
    Xu, R
    Ramakrishna, N
    Weaver, S
    Kracher, J
    Bradshaw, J
    Levy, B
    Bailey, E
    Kesari, S
    Maher, EA
    Henson, J
    Black, PM
    NEURO-ONCOLOGY, 2004, 6 (04) : 385 - 385
  • [30] PHASE II STUDY OF PEMBROLIZUMAB PLUS SURVAXM FOR GLIOBLASTOMA AT FIRST RECURRENCE
    Ahluwalia, Manmeet
    Peereboom, David
    Rauf, Yasmeen
    Schilero, Cathy
    Ciolfi, Marci
    Ciesielski, Michael
    Fenstermaker, Robert
    NEURO-ONCOLOGY, 2020, 22 : 34 - 35
12345